Natixis Advisors’s Atara Biotherapeutics ATRA Stock Holding History

Natixis Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-779	Closed	-$307K	–	1423
2021 Q4	$307K	Sell	779 -5	-0.6%	-$2.1K	﹤0.01%	1317
2021 Q3	$351K	Buy	784 +8	+1%	+$2.87K	﹤0.01%	1253
2021 Q2	$302K	Sell	776 -5	-0.6%	-$1.78K	﹤0.01%	1278
2021 Q1	$280K	Sell	781 -88	-10%	-$38.9K	﹤0.01%	1235
2020 Q4	$426K	Buy	+869	New	+$401K	﹤0.01%	1139

Other funds holding ATRA

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Natixis Advisors's ATRA Position: Q1 2022 in Review

Natixis Advisors sold out of Atara Biotherapeutics (ATRA) in Q1 2022, closing a stake of 779 shares — an estimated $307K sold.

Natixis Advisors first reported a position in ATRA in Q4 2020 and held it in 5 quarters. The position peaked at $426K in Q4 2020. 144 funds tracked by Wall St. Rank hold ATRA as of Q1 2022.

Natixis Advisors reported no remaining Atara Biotherapeutics position as of Q1 2022 after selling out during the quarter.
Natixis Advisors sold 779 Atara Biotherapeutics shares in Q1 2022, an estimated $307K.
Natixis Advisors first reported a position in Atara Biotherapeutics in Q4 2020 and held it in 5 quarters.
Natixis Advisors's Atara Biotherapeutics position peaked at $426K in Q4 2020.
144 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2022.

Based on Natixis Advisors's 13F filing for Q1 2022, filed 12 May 2022.